+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Anti-Obesity Drugs market set to grow to $6.3bn by 2023” says new Visiongain report

20 November 2018
Pharma

Visiongain has launched a new pharma report: Global Anti-obesity Drugs Market Report : Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

The Global Anti-Obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MoA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.

The lead analyst of the report commented "During the forecast period, the global market is driven by the raising prevalence of overweight and obesity population; increasing awareness about the disease; growing diagnosis & treatment rates; obesity being recognized as a disease, adoption of national and international level policies by various countries.

In the global market, challenges continue with huge healthcare budget constraints, weak late-stage promising pipeline, generic competition, unavailability of safer & effective treatments, and availability of alternate therapies."

Leading companies featured in the report include Eisai/Arena, GlaxoSmithKline (GSK), Novo Nordisk, Orexigen/Takeda, Roche, Teva, Vivus

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022

Read

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever